Edition:
United Kingdom

Editas Medicine Inc (EDIT.OQ)

EDIT.OQ on NASDAQ Stock Exchange Global Select Market

33.28USD
20 Feb 2018
Change (% chg)

$-0.54 (-1.60%)
Prev Close
$33.82
Open
$33.80
Day's High
$34.97
Day's Low
$33.05
Volume
293,266
Avg. Vol
420,961
52-wk High
$41.60
52-wk Low
$13.13

Chart for

About

Editas Medicine, Inc. is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly... (more)

Overall

Beta: --
Market Cap(Mil.): $1,043.82
Shares Outstanding(Mil.): 41.74
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Adverum Biotechnologies Extends Collaboration Agreement With Editas Medicine

* ANNOUNCES EXTENSION OF ITS COLLABORATION AGREEMENT WITH EDITAS MEDICINE INC

25 Jan 2018

BRIEF-Editas Medicine Files For Potential Stock Shelf, Size Undisclosed - SEC Filing

* EDITAS MEDICINE INC FILES FOR POTENTIAL STOCK SHELF, SIZE UNDISCLOSED - SEC FILING Source text: (http://bit.ly/2zhhSfB) Further company coverage:

22 Dec 2017

BRIEF-Editas Medicine Announces Pricing Of $50 Mln Offering Of Common Stock

* EDITAS MEDICINE, INC., ANNOUNCES PRICING OF $50 MILLION OFFERING OF COMMON STOCK

06 Dec 2017

BRIEF-Editas Medicine Announces Offering Of Common Stock

* EDITAS MEDICINE INC - INTENDS TO OFFER AND SELL $50 MILLION OF SHARES OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING Source text for Eikon: Further company coverage:

05 Dec 2017

BRIEF-Editas Medicine announces Q3 loss per share $0.64

* Editas Medicine announces third quarter 2017 results and update

07 Nov 2017

BRIEF-Editas receives EMA's orphan medicinal product designation for EDIT-101

* Editas Medicine receives EMA's orphan medicinal product designation for EDIT-101 for the treatment of LCA10

26 Sep 2017

BRIEF-Editas Medicine Inc initiates clinical natural history study of Leber Congenital Amaurosis type 10

* Editas Medicine Inc - announced that company initiated a clinical natural history study of Leber Congenital Amaurosis type 10 (LCA10)

12 Sep 2017

Earnings vs. Estimates